declares having received honoraria from Novo Nordisk, Eli Lilly, Akebia Therapeutics, Ardelyx, Becton Dickinson, Endologix, FibroGen, GSK, Medtronic, Neovasc, Provention Bio, ReCor, BrainStorm Cell Therapeutics, Alnylam and Intarcia for consulting activities, and research funding to his institution from AbbVie, Esperion, AstraZeneca, CSL Behring, Novartis and Eli Lilly
For stronger data integrity, studies should include suitable controls, repeat measurements, documented acceptance criteria, and a clear distinction between exploratory findings and validated conclusions
Why Choose Wound Warrior
While clinical studies have demonstrated its fat-reducing potential, AOD-9604 has not been fully validated as an FDA-approved weight loss therapy